Leadership Team

Lars is a Founding Investor of Evaxion and has previously been involved in multiple startups and early ventures. He began his career as a medical doctor and worked for several years as a clinician.

Since then, Lars has gained extensive experience within the vaccine industry, first at Pfizer and then 10 years as part of Senior Management at Bavarian Nordic, a listed immuno-oncology and vaccine company.

Niels received his MD from the University of Copenhagen and BA of Economics from Copenhagen Business School. He has worked as a Medical Director within the area of Companion Diagnostics and prior to that as a Medical Advisor within the area of cancer and biopharmaceuticals for AstraZeneca. Niels began this career at Servier Pharmaceuticals as Marketing Manager. Until August 2017, Niels was CEO of Evaxion, and in 2016, he was awarded “CEO of the Year” in the vaccine industry by European CEO.

Andreas is an experienced bioinformatician from the Technical University of Denmark. Prior to Evaxion, Andreas spent six years at Novo Nordisk developing in silico platforms.

Since the founding of Evaxion in 2008, Andreas has worked on developing Evaxion’s in silico platforms including EDEN and PIONER and numerous other in silico tools enabling vaccine discovery in the area of infectious diseases and immuno-oncology.

Erik received his MD from University of Copenhagen, and subsequently earned a PhD, became a board certified medical specialist, and was awarded a Doctorate Dissertation (DMSc). He also holds an Executive Master of Business Strategy from Copenhagen Business School.

He has held numerous research and clinical positions, and was a medical manager at Statens Serum Institute. Over the past 15 years he has gained profound experience in leadership, project management, clinical development and medical affairs during tenures at Bavarian Nordic, Sandia National Laboratories, Novo Nordisk, Novartis and Seagen.

Birgitte Rønø, PhD, joined us as Senior Director, Immuno-Oncology in September 2017. Dr. Rønø has developed and led our pre-clinical and early clinical oncology pipeline. In September 2021, Dr. Rønø was appointed Chief Scientific Officer. Dr Rønø has more than 15 years’ experience in biopharmaceutical drug discovery from academia and industry. Prior to joining Evaxion, Dr. Rønø served as a specialist, team leader and project manager at Novo Nordisk, from 2013-2017, where she was leading early drug discovery projects, evaluating in-licensing opportunities, and supporting drug development projects with pre-clinical and biomarker expertise. Dr. Rønø holds a bachelor’s degree in medicine and a master’s degree in human biology, both from the University of Copenhagen, Denmark. Dr. Rønø received her Ph.D. in experimental oncology and immunology from National Institutes of Health, Bethesda, USA and Copenhagen University Hospital, Denmark.